Released Aug 14, 2012, during market hours
10-Q filed Aug 14, 2012, 45 days after period end · 0001213900-12-004513
Q2 2012 · 10-Q
Revenue$7.43M$7.43M +48.9% vs Q2 2011+63.7% vs Q1 2012
Net Income$272.41K$272.41K N/M vs Q2 2011N/M vs Q1 2012
EPS Diluted$0.02$0.02 N/M vs Q2 2011N/M vs Q1 2012
Gross Profit$2,740,523+54.7%
Operating Income$1,497,349+552.2%
Operating Cash Flowderived$1,767,943−1.4%
Free Cash Flowderived$1,573,230−17.3%
Margins · derived
Gross margin36.9%+1.4 pt vs Q2 2011
Operating margin20.1%+15.5 pt vs Q2 2011
Net margin3.7%+36.8 pt vs Q2 2011
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q2 2012 | Q2 2011 | Q2 2010 |
|---|---|---|---|
| Revenue | $7.43M | $4.99M | $4.27M |
| Net Income | $272.41K | -$1.65M | $568.26K |
| EPS Diluted | $0.02 | -$0.12 | $0.07 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Tanke Biosciences Corp · CIK 1452011 · Engraved from SEC EDGAR